| Year |
Citation |
Score |
| 2022 |
Barajas RF, Ambady P, Link J, Krohn KA, Raslan A, Mallak N, Woltjer R, Muldoon L, Neuwelt EA. [F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab. Neuro-Oncology Practice. 9: 246-250. PMID 35601969 DOI: 10.1093/nop/npac021 |
0.31 |
|
| 2020 |
Muzi M, Wolsztynski E, Fink JR, O'Sullivan JN, O'Sullivan F, Krohn KA, Mankoff DA. Assessment of the Prognostic Value of Radiomic Features in F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial. Tomography (Ann Arbor, Mich.). 6: 14-22. PMID 32280746 DOI: 10.18383/j.tom.2019.00023 |
0.308 |
|
| 2018 |
Manohar P, Peterson L, Wu V, Jenkins I, Novakova-Jiresova A, Specht JM, Link J, Krohn KA, Kinahan P, Mankoff DA, Linden HM. 18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer. Journal of Clinical Oncology. 36: 1063-1063. DOI: 10.1200/Jco.2018.36.15_Suppl.1063 |
0.382 |
|
| 2016 |
Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27342400 DOI: 10.1158/1078-0432.Ccr-16-0362 |
0.406 |
|
| 2016 |
Muzi M, Krohn KA. Imaging Hypoxia with 18F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 497-8. PMID 26912434 DOI: 10.2967/Jnumed.115.171694 |
0.36 |
|
| 2016 |
Currin E, Peterson LM, Schubert EK, Link JM, Krohn KA, Livingston RB, Mankoff DA, Linden HM. Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 144-7. PMID 26850484 DOI: 10.6004/Jnccn.2016.0017 |
0.345 |
|
| 2016 |
Roberts TK, Peterson L, Kurland B, Novakova A, Shields A, Doot RK, Schubert EK, Gadi VK, Specht JM, Gralow J, Eary JF, Muzi M, Link J, Krohn KA, Mankoff DA, et al. Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer. Journal of Clinical Oncology. 34: e12039-e12039. DOI: 10.1200/Jco.2016.34.15_Suppl.E12039 |
0.387 |
|
| 2015 |
Fink JR, Muzi M, Peck M, Krohn KA. Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1554-61. PMID 26294301 DOI: 10.2967/Jnumed.113.131516 |
0.375 |
|
| 2015 |
Muzi M, Peterson LM, O'Sullivan JN, Fink JA, Rajendran JG, McLaughlin LJ, Muzi JP, Mankoff DA, Krohn KA. [F-18]-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients using Image-derived Blood Surrogate Tissue Reference Regions. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26112020 DOI: 10.2967/Jnumed.115.158717 |
0.396 |
|
| 2015 |
Peck M, Pollack HA, Friesen A, Muzi M, Shoner SC, Shankland EG, Fink JR, Armstrong JO, Link JM, Krohn KA. Applications of PET imaging with the proliferation marker [18F]-FLT. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. 59: 95-104. PMID 25737423 |
0.318 |
|
| 2015 |
Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Seminars in Nuclear Medicine. 45: 151-62. PMID 25704387 DOI: 10.1053/J.Semnuclmed.2014.10.006 |
0.398 |
|
| 2015 |
Plotnik DA, Wu S, Linn GR, Yip FC, Comandante NL, Krohn KA, Toyohara J, Schwartz JL. In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells. Nuclear Medicine and Biology. 42: 470-4. PMID 25659855 DOI: 10.1016/J.Nucmedbio.2014.12.005 |
0.399 |
|
| 2015 |
Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, Mrugala MM, Rockhill JK, Kinahan P, Krohn KA, Swanson KR. A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET. Journal of the Royal Society, Interface / the Royal Society. 12. PMID 25540239 DOI: 10.1098/Rsif.2014.1174 |
0.358 |
|
| 2014 |
O'Sullivan F, Muzi M, Mankoff DA, Eary JF, Spence AM, Krohn KA. VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLES. The Annals of Applied Statistics. 8: 1065-1094. PMID 25392718 DOI: 10.1214/14-Aoas732 |
0.364 |
|
| 2014 |
Linden HM, Kurland BF, Link J, Novakova A, Chai X, Specht JM, Gadi VK, Gralow J, Schubert EK, Peterson L, Eary JF, Shields A, Mankoff DA, Krohn KA. A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular imaging correlates. Journal of Clinical Oncology. 32: 556-556. DOI: 10.1200/Jco.2014.32.15_Suppl.556 |
0.314 |
|
| 2014 |
Murphy S, Hawe D, Hernandez F, Wolsztynski E, Huang J, O'Sullivan J, Muzi M, Eary J, Krohn K, O'Sullivan F. 235 Kinetic analysis of dynamic 11C thymidine PET imaging studies: Compartmental and nonparametric approaches European Journal of Cancer. 50: 79. DOI: 10.1016/S0959-8049(14)70361-2 |
0.34 |
|
| 2014 |
Hernandez F, Hawe D, Murphy S, O'Sullivan J, Wolsztynski E, Huang J, Muzi M, Eary J, Krohn K, O'Sullivan F. 234 Kinetic analysis of dynamic 11C-verapamil PET study: Compartmental v adaptive mixture models comparison European Journal of Cancer. 50: 79. DOI: 10.1016/S0959-8049(14)70360-0 |
0.369 |
|
| 2014 |
Hawe D, Hernandez F, Murphy S, Wolsztynski E, Huang J, O'Sullivan J, Muzi M, Eary J, Krohn K, O'Sullivan F. 197 Statistical aspects of kinetic analysis of gliomas with FDG-PET European Journal of Cancer. 50: 64. DOI: 10.1016/S0959-8049(14)70323-5 |
0.365 |
|
| 2013 |
Eary JF, Krohn KA. Standards for reporting PET clinical trials Journal of Nuclear Medicine. 54: 1516-1517. PMID 23940302 DOI: 10.2967/Jnumed.113.127845 |
0.354 |
|
| 2013 |
Hawkins-Daarud A, Rockne R, Kinahan P, Muzi M, Alessio A, Krohn KA, Swanson K. Quantifying the impact of antiangiogenic therapy on hypoxia and implications for radiation therapy in glioblastoma multiforme with a biomathematical model. Journal of Clinical Oncology. 31: e13028-e13028. DOI: 10.1200/Jco.2013.31.15_Suppl.E13028 |
0.338 |
|
| 2013 |
Richards TL, Muzi M, Marro K, Fink JR, Rockhill JK, Krohn K. Abstract B150: Are MRI/MRS methods complementary to FMISO-PET for evaluating hypoxia. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B150 |
0.39 |
|
| 2013 |
Muzi M, O'Sullivan J, Eary JF, Krohn KA. Abstract B149: Quantitative FMISO imaging to assess regional tumor hypoxia as a predictor of response to therapy. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B149 |
0.369 |
|
| 2013 |
Eary JF, Link JM, Muzi M, O'Sullivan F, Rockhill JK, Fink JR, Linden HM, Krohn KA. Abstract B147: Tumor response imaging with [F-18] fluorothymidine (FLT). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B147 |
0.413 |
|
| 2013 |
Gao W, Nyflot M, Rajendran J, Hendrickson K, Krohn K. Local Recurrence and Progression Is Spatially Correlated With Focal Pretreatment FMISO PET Uptake in Head and Neck SCC International Journal of Radiation Oncology*Biology*Physics. 87: S440. DOI: 10.1016/J.Ijrobp.2013.06.1160 |
0.317 |
|
| 2012 |
Plotnik DA, Asher C, Chu SK, Miyaoka RS, Garwin GG, Johnson BW, Li T, Krohn KA, Schwartz JL. Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549 tumor cells grown as tumor xenografts in vivo Nuclear Medicine and Biology. 39: 1161-1166. PMID 22985987 DOI: 10.1016/J.Nucmedbio.2012.07.007 |
0.381 |
|
| 2012 |
Plotnik DA, McLaughlin LJ, Krohn KA, Schwartz JL. The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells Nuclear Medicine and Biology. 39: 970-976. PMID 22560972 DOI: 10.1016/J.Nucmedbio.2012.03.009 |
0.361 |
|
| 2012 |
Gu S, Chakraborty G, Champley K, Alessio AM, Claridge J, Rockne R, Muzi M, Krohn KA, Spence AM, Alvord EC, Anderson AR, Kinahan PE, Swanson KR. Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images. Mathematical Medicine and Biology : a Journal of the Ima. 29: 31-48. PMID 21562060 DOI: 10.1093/Imammb/Dqr002 |
0.421 |
|
| 2012 |
Krohn KA, Moerlein SM, Link JM, Welch MJ. Hot atom chemistry and radiopharmaceuticals Aip Conference Proceedings. 1509: 3-15. DOI: 10.1063/1.4773930 |
0.581 |
|
| 2012 |
Krohn K, Muzi M, Link J, Richards T, Fink J, Rockhill J, Eary J. 455 Role of Hypoxia Imaging with [F-18]FMISO-PET and BOLD-MRI in Clinical Trials European Journal of Cancer. 48: 141. DOI: 10.1016/S0959-8049(12)72253-0 |
0.389 |
|
| 2012 |
Eary J, Link J, Muzi M, Estey E, Kauno K, Krohn K. 453 [F-18] Fluorothymidine (FLT) PET Imaging of Response of Acute Myeloid Leukemia to Chemotherapy European Journal of Cancer. 48: 140. DOI: 10.1016/S0959-8049(12)72251-7 |
0.392 |
|
| 2012 |
O'Sullivan F, Muzi M, Huang J, Eary J, Link J, Krohn K. 261 A Fully Automatic Procedure for Image Derived Blood Extraction, Including Assessment of Metabolite, in Dynamic PET Fluorothymidine (FLT) Studies European Journal of Cancer. 48: 80. DOI: 10.1016/S0959-8049(12)72059-2 |
0.338 |
|
| 2011 |
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1541-9. PMID 21903739 DOI: 10.2967/Jnumed.111.091439 |
0.334 |
|
| 2011 |
Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 369-75. PMID 21872957 DOI: 10.1016/J.Radonc.2011.07.029 |
0.406 |
|
| 2011 |
Eary JF, Link JM, Muzi M, Conrad EU, Mankoff DA, White JK, Krohn KA. Multiagent PET for risk characterization in sarcoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 541-6. PMID 21421714 DOI: 10.2967/Jnumed.110.083717 |
0.374 |
|
| 2010 |
Plotnik DA, Emerick LE, Krohn KA, Unadkat JD, Schwartz JL. Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1464-71. PMID 20720049 DOI: 10.2967/Jnumed.110.076794 |
0.3 |
|
| 2010 |
O'Sullivan F, Kirrane J, Muzi M, O'Sullivan JN, Spence AM, Mankoff DA, Krohn KA. Kinetic quantitation of cerebral PET-FDG studies without concurrent blood sampling: statistical recovery of the arterial input function. Ieee Transactions On Medical Imaging. 29: 610-24. PMID 19709971 DOI: 10.1109/Tmi.2009.2029096 |
0.344 |
|
| 2010 |
Eary J, Link J, Conrad E, Muzi M, O'Sullivan F, Krohn K. 650 Multiparameter PET imaging for assessing risk/outcome in sarcoma European Journal of Cancer Supplements. 8: 203. DOI: 10.1016/S1359-6349(10)72357-0 |
0.327 |
|
| 2009 |
O'Sullivan F, Muzi M, Spence AM, Mankoff DM, O'Sullivan JN, Fitzgerald N, Newman GC, Krohn KA. Nonparametric Residue Analysis of Dynamic PET Data With Application to Cerebral FDG Studies in Normals. Journal of the American Statistical Association. 104: 556-571. PMID 19830267 DOI: 10.1198/Jasa.2009.0021 |
0.353 |
|
| 2009 |
Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC, Krohn KA, Spence AM, Swanson KR. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Research. 69: 4502-9. PMID 19366800 DOI: 10.1158/0008-5472.Can-08-3884 |
0.416 |
|
| 2009 |
Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 11: 343-55. PMID 19326172 DOI: 10.1007/S11307-009-0215-2 |
0.418 |
|
| 2009 |
Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, Adamsen TC, Krohn KA, Spence AM. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 36-44. PMID 19091885 DOI: 10.2967/Jnumed.108.055467 |
0.765 |
|
| 2008 |
Li X, Link JM, Stekhova S, Yagle KJ, Smith C, Krohn KA, Tait JF. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjugate Chemistry. 19: 1684-8. PMID 18627198 DOI: 10.1021/Bc800164D |
0.36 |
|
| 2008 |
Krohn KA, Yeuh B. Novel imaging approaches to head and neck cancer. Seminars in Oncology. 35: 262-73. PMID 18544441 DOI: 10.1053/J.Seminoncol.2008.03.001 |
0.347 |
|
| 2008 |
Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 10: 271-80. PMID 18543042 DOI: 10.1007/S11307-008-0151-6 |
0.366 |
|
| 2008 |
Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 129S-48S. PMID 18523070 DOI: 10.2967/Jnumed.107.045914 |
0.34 |
|
| 2008 |
Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2623-30. PMID 18451225 DOI: 10.1158/1078-0432.Ccr-07-4995 |
0.761 |
|
| 2008 |
Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T, Krohn KA. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 367-74. PMID 18287268 DOI: 10.2967/Jnumed.107.047506 |
0.364 |
|
| 2008 |
Stelzer KJ, Douglas JG, Mankoff DA, Silbergeld DL, Krohn KA, Laramore GE, Spence AM. Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme. Neuro-Oncology. 10: 88-92. PMID 18055860 DOI: 10.1215/15228517-2007-044 |
0.362 |
|
| 2008 |
Rajendran JG, Krohn KA. Positron emission tomography imaging of tumor hypoxia and angiogenesis: Imaging biology and guiding therapy Cancer Imaging. 201-209. DOI: 10.1016/B978-012374212-4.50091-2 |
0.389 |
|
| 2007 |
Krohn KA, O'Sullivan F, Crowley J, Eary JF, Linden HM, Link JM, Mankoff DA, Muzi M, Rajendran JG, Spence AM, Swanson KR. Challenges in clinical studies with multiple imaging probes. Nuclear Medicine and Biology. 34: 879-85. PMID 17921038 DOI: 10.1016/J.Nucmedbio.2007.07.014 |
0.308 |
|
| 2007 |
Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3460-9. PMID 17575208 DOI: 10.1158/1078-0432.Ccr-07-0074 |
0.418 |
|
| 2007 |
Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. European Radiology. 17: 861-72. PMID 17043737 DOI: 10.1007/S00330-006-0431-Y |
0.338 |
|
| 2007 |
Linden HM, Mankoff DA, Krohn KA, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Kurland B, Peterson L, Schubert EK. PET FES measures in vivo pharmacodynamics of endocrine therapy Journal of Clinical Oncology. 25: 14110-14110. DOI: 10.1200/Jco.2007.25.18_Suppl.14110 |
0.333 |
|
| 2007 |
Nurani R, Rajendran J, Austin-Seymour M, Scharnhorst J, Krohn K, Laramore G. The Predictive Utility of PET-Misonidazole in Locally Advanced Head and Neck Cancer Treated with Radiotherapy International Journal of Radiation Oncology*Biology*Physics. 69: S140-S141. DOI: 10.1016/J.Ijrobp.2007.06.012 |
0.301 |
|
| 2006 |
Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5435-41. PMID 17000677 DOI: 10.1158/1078-0432.Ccr-05-1773 |
0.418 |
|
| 2006 |
Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. European Journal of Nuclear Medicine and Molecular Imaging. 33: 44-53. PMID 16763816 DOI: 10.1007/S00259-006-0135-1 |
0.377 |
|
| 2006 |
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2793-9. PMID 16682724 DOI: 10.1200/Jco.2005.04.3810 |
0.336 |
|
| 2006 |
Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Annals of Surgical Oncology. 13: 187-97. PMID 16418883 DOI: 10.1245/Aso.2006.04.022 |
0.41 |
|
| 2006 |
Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M, Silbergeld DL, Rostomily RC, Scharnhorst J, Spence AM. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. International Journal of Radiation Oncology, Biology, Physics. 64: 886-91. PMID 16242251 DOI: 10.1016/J.Ijrobp.2005.08.013 |
0.398 |
|
| 2006 |
Linden HM, Stekhova S, Link JM, Livingston RB, Gralow JR, Ellis GK, Peterson LM, Schubert EK, Krohn KA, Mankoff DA. Understanding resistance to hormonal therapy in estrogen avid breast cancer Journal of Clinical Oncology. 24: 566-566. DOI: 10.1200/Jco.2006.24.18_Suppl.566 |
0.311 |
|
| 2006 |
Eary JF, Conrad E, Link J, Cizik A, Mankoff D, Krohn K. Risk assessment in high grade sarcoma patients during neoadjuvant chemotherapy using multiple tracer PET Journal of Clinical Oncology. 24: 20006-20006. DOI: 10.1200/Jco.2006.24.18_Suppl.20006 |
0.391 |
|
| 2006 |
Spence A, Muzi M, Swanson K, Rockhill J, Rajendran J, Adamsen T, Link J, Scharnhorst J, Krohn K. 531 POSTER Hypoxia assessed in malignant gliomas with [F-18]-fluoromisonidazole (FMISO) PET before and after radiotherapy (RT) European Journal of Cancer Supplements. 4: 161. DOI: 10.1016/S1359-6349(06)70536-5 |
0.41 |
|
| 2005 |
Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nuclear Medicine and Biology. 32: 663-71. PMID 16243640 DOI: 10.1016/J.Nucmedbio.2005.04.004 |
0.409 |
|
| 2005 |
Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, Leblanc M, Krohn K, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head & Neck. 27: 478-87. PMID 15772953 DOI: 10.1002/Hed.20177 |
0.384 |
|
| 2005 |
Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiologic Clinics of North America. 43: 169-87. PMID 15693655 DOI: 10.1016/J.Rcl.2004.08.004 |
0.38 |
|
| 2005 |
Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiologic Clinics of North America. 43: 153-67. PMID 15693654 DOI: 10.1016/J.Rcl.2004.09.005 |
0.421 |
|
| 2005 |
Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellyn B, Mattes D, Meyer J, Phillips M, Leblanc M, Kinahan P, Krohn K, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics. 61: 129-36. PMID 15629603 DOI: 10.1016/J.Ijrobp.2004.03.040 |
0.37 |
|
| 2005 |
Adamsen TCH, Grierson JR, Krohn KA. A new synthesis of the labeling precursor for [18F]- fluoromisonidazole Journal of Labelled Compounds and Radiopharmaceuticals. 48: 923-927. DOI: 10.1002/Jlcr.1001 |
0.383 |
|
| 2004 |
Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, Krohn K. FDG-PET prediction of head and neck squamous cell cancer outcomes. Archives of Otolaryngology--Head & Neck Surgery. 130: 1361-7. PMID 15611393 DOI: 10.1001/Archotol.130.12.1361 |
0.371 |
|
| 2004 |
Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 45: 1653-9. PMID 15471829 |
0.327 |
|
| 2004 |
Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nuclear Medicine and Biology. 31: 829-37. PMID 15464384 DOI: 10.1016/J.Nucmedbio.2004.06.004 |
0.379 |
|
| 2004 |
Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake. Nuclear Medicine and Biology. 31: 419-23. PMID 15093811 DOI: 10.1016/J.Nucmedbio.2004.01.002 |
0.319 |
|
| 2004 |
Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2245-52. PMID 15073099 DOI: 10.1158/1078-0432.Ccr-0688-3 |
0.433 |
|
| 2004 |
Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, Link JM, Krohn KA. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjugate Chemistry. 15: 373-9. PMID 15025534 DOI: 10.1021/Bc0300394 |
0.399 |
|
| 2004 |
Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM. [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro. Nuclear Medicine and Biology. 31: 1-9. PMID 14741565 DOI: 10.1016/S0969-8051(02)00449-3 |
0.746 |
|
| 2003 |
Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method? Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 5: 281-5. PMID 14630508 DOI: 10.1016/J.Mibio.2003.09.002 |
0.361 |
|
| 2003 |
Schwartz DL, Rajendran J, Yueh B, Coltrera M, Anzai Y, Krohn K, Eary J. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Archives of Otolaryngology--Head & Neck Surgery. 129: 1173-8. PMID 14623746 DOI: 10.1001/Archotol.129.11.1173 |
0.366 |
|
| 2003 |
Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression European Journal of Nuclear Medicine and Molecular Imaging. 30: 695-704. PMID 12632200 DOI: 10.1007/S00259-002-1096-7 |
0.443 |
|
| 2003 |
Schwartz D, Ford E, Meyer J, Rajendran J, Lewellen B, Yueh B, Coltrera M, Virgin J, Anzai Y, Kinahan P, Phillips M, Krohn K. Co-registered FDG-PET/CT imaging for staging and IMRT treatment planning for squamous cell carcinoma of the head and neck International Journal of Radiation Oncology*Biology*Physics. 57: S156-S157. DOI: 10.1016/S0360-3016(03)00931-3 |
0.33 |
|
| 2002 |
Wells JM, Mankoff DA, Muzi M, O'Sullivan F, Eary JF, Spence AM, Krohn KA. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Molecular Imaging. 1: 151-9. PMID 12920853 DOI: 10.1162/153535002760235454 |
0.356 |
|
| 2002 |
Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O'Sullivan F, Vernon CB, Link JM, Krohn KA. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Molecular Imaging. 1: 145-50. PMID 12920852 DOI: 10.1162/153535002760235445 |
0.368 |
|
| 2002 |
Spence AM, Muzi M, Krohn KA. Molecular imaging of regional brain tumor biology. Journal of Cellular Biochemistry. Supplement. 39: 25-35. PMID 12552599 DOI: 10.1002/Jcb.10406 |
0.415 |
|
| 2001 |
Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy Journal of Clinical Pharmacology. 41. PMID 11452736 DOI: 10.1177/0091270001417014 |
0.402 |
|
| 2001 |
Muzi M, Freeman SD, Burrows RC, Wiseman RW, Link JM, Krohn KA, Graham MM, Spence AM. Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. Nuclear Medicine and Biology. 28: 107-16. PMID 11295420 DOI: 10.1016/S0969-8051(00)00201-8 |
0.397 |
|
| 2000 |
Eary JF, Krohn KA. Positron emission tomography: Imaging tumor response European Journal of Nuclear Medicine. 27: 1737-1739. PMID 11189933 DOI: 10.1007/S002590000322 |
0.366 |
|
| 1999 |
Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Research. 59: 615-21. PMID 9973209 |
0.314 |
|
| 1998 |
Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, Zheng M, Lewellen B, Lewellen TK, Grierson JR, Krohn KA. Carbon-11-thymidine and FDG to measure therapy response. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 39: 1757-62. PMID 9776283 |
0.301 |
|
| 1998 |
Tewson TJ, Krohn KA. PET radiopharmaceuticals: State-of-the-art and future prospects Seminars in Nuclear Medicine. 28: 221-234. PMID 9704364 DOI: 10.1016/S0001-2998(98)80028-7 |
0.352 |
|
| 1996 |
Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients International Journal of Radiation Oncology Biology Physics. 36: 417-428. PMID 8892467 DOI: 10.1016/S0360-3016(96)00325-2 |
0.41 |
|
| 1995 |
Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. International Journal of Radiation Oncology, Biology, Physics. 33: 391-8. PMID 7673026 DOI: 10.1016/0360-3016(95)00170-4 |
0.431 |
|
| 1995 |
Spence AM, Rasey JS, Dwyer-Hansen L, Grunbaum Z, Livesey J, Chin L, Nelson N, Stein D, Krohn KA, Ali-Osman F. Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 35: 216-26. PMID 7480825 DOI: 10.1016/0167-8140(95)01543-P |
0.307 |
|
| 1992 |
Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. International Journal of Radiation Oncology, Biology, Physics. 22: 199-212. PMID 1727119 DOI: 10.1016/0360-3016(92)91001-4 |
0.448 |
|
| 1991 |
Biskupiak JE, Grierson JR, Rasey JS, Martin GV, Krohn KA. Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging Journal of Medicinal Chemistry. 34: 2165-2168. PMID 2066990 DOI: 10.1021/Jm00111A036 |
0.359 |
|
| 1989 |
Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia International Journal of Radiation Oncology, Biology, Physics. 17: 985-991. PMID 2808061 DOI: 10.1016/0360-3016(89)90146-6 |
0.401 |
|
| 1989 |
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody Journal of Clinical Oncology. 7: 1027-1038. PMID 2666588 DOI: 10.1200/Jco.1989.7.8.1027 |
0.311 |
|
| 1989 |
Koh W, Rasey JS, Grierson JR, Graham MM, Modell HI, Russell KJ, Griffin TW, Krohn KA. Imaging tumor hypoxia using positron emission tomography imaging of [F-18] fluoromisonidazole: A report of work during the astro research year International Journal of Radiation Oncology*Biology*Physics. 17: 198. DOI: 10.1016/0360-3016(89)90789-X |
0.402 |
|
| 1989 |
Grierson J, Link J, Mathis C, Rasey J, Krohn K. A radiosynthesis of [F-18]fluoromisonidazole Journal of Labelled Compounds and Radiopharmaceuticals. 26: 6-7. DOI: 10.1002/Jlcr.2580260104 |
0.341 |
|
| 1988 |
Shields AF, Graham MM, Modell HI, Lewellen TK, Grierson JR, Link JM, Krohn KA. PET IMAGING WITH C-11 THYMIDINE: DEVELOPMENT OF BIOCHEMICAL AND KINETIC MODELS. Clinical Nuclear Medicine. 13: P24. DOI: 10.1097/00003072-198809001-00059 |
0.35 |
|
| 1987 |
Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, Krohn KA. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells Radiation Research. 111: 292-304. PMID 3628717 DOI: 10.2307/3576986 |
0.336 |
|
| 1987 |
Mathias CJ, Welch MJ, Kilbourn MR, Jerabek PA, Patrick TB, Raichle ME, Krohn KA, Rasey JS, Shaw DW. Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. Life Sciences. 41: 199-206. PMID 3600179 DOI: 10.1016/0024-3205(87)90494-2 |
0.493 |
|
| 1986 |
Rasey JS, Krohn KA, Magee S, Nelson N, Chin L. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor Radiation Research. 108: 167-175. PMID 3024202 DOI: 10.2307/3576822 |
0.328 |
|
| 1986 |
Rasey JS, Krohn KA, Grunbaum Z, Spence AM, Menard TW, Wade RA. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689). Radiation Research. 106: 366-79. PMID 3012625 DOI: 10.2307/3576744 |
0.301 |
|
| 1985 |
Larson SM, Carrasquillo JA, McGuffin RW, Krohn KA, Ferens JM, Hill LD, Beaumier PL, Reynolds JC, Hellström KE, Hellström I. Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience Radiology. 155: 487-492. PMID 3983400 DOI: 10.1148/Radiology.155.2.3983400 |
0.314 |
|
| 1983 |
Larson SM, Carrasquillo JA, Krohn KA, McGuffin RW, Williams DL, Hellström I, Lyster D. Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies Journal of the American Medical Association. 249: 811-812. PMID 6600501 DOI: 10.1001/Jama.249.6.811 |
0.304 |
|
| 1983 |
Larson SM, Carrasquillo JA, Krohn KA, Brown JP, McGuffin RW, Ferens JM, Graham MM, Hill LD, Beaumier PL, Hellström KE. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. The Journal of Clinical Investigation. 72: 2101-14. PMID 6196380 DOI: 10.1172/Jci111175 |
0.324 |
|
| 1982 |
Rasey JS, Krohn KA, Freauff S. Bromomisonidazole: Synthesis and characterization of a new radiosensitizer Radiation Research. 91: 542-554. PMID 7122830 DOI: 10.2307/3575891 |
0.334 |
|
| 1977 |
Krohn KA, Knight LC, Harwig JF, Welch MJ. Differences in the sites of iodination of proteins following four methods of radioiodination. Biochimica Et Biophysica Acta. 490: 497-505. PMID 836887 DOI: 10.1016/0005-2795(77)90026-5 |
0.324 |
|
| 1977 |
Krohn KA, Meyers J, DeNardo GL. Comparison of I-bleomycin prepared by two methods stability and pharmacokinetics in tumor-bearing mice. Radiology. 122: 179-82. PMID 63131 DOI: 10.1148/122.1.179 |
0.309 |
|
| 1975 |
Jiang VW, Krohn KA, Welch MJ. Intramolecular effects of radioiodine decay in o-iodophenol, a model for radioiodinated proteins. Journal of the American Chemical Society. 97: 6551-6. PMID 1184870 DOI: 10.1021/Ja00855A044 |
0.377 |
|
| 1975 |
Manning RG, Krohn KA, Root JW. Significance of limiting low pressure product yields from energetic atomic exchange reactions Chemical Physics Letters. 35: 544-549. DOI: 10.1016/0009-2614(75)85664-8 |
0.646 |
|
| 1974 |
Krohn KA, Welch MJ. Studies of radioiodinated fibrinogen. II. Lactoperoxidase iodination of fibrinogen and model compounds. The International Journal of Applied Radiation and Isotopes. 25: 315-23. PMID 4472325 DOI: 10.1016/0020-708X(74)90041-6 |
0.349 |
|
| 1973 |
Loberg MD, Krohn KA, Welch MJ. Reactions of recoil iodine formed by the xenon-125 .far. iodine-123 system with simple hydrocarbons. II. Pressure studies on the methane and ethane systems Journal of the American Chemical Society. 95: 5496-5503. DOI: 10.1021/Ja00798A011 |
0.39 |
|
| 1973 |
LOBERG MD, KROHN KA, WELCH MJ. ChemInform Abstract: REACTIONS OF RECOIL IODINE FORMED BY THE (123)XE-(123)I SYSTEM WITH SIMPLE HYDROCARBONS PART 2, PRESSURE STUDIES ON THE METHANE AND ETHANE SYSTEMS Chemischer Informationsdienst. 4: no-no. DOI: 10.1002/Chin.197343205 |
0.396 |
|
| 1972 |
Krohn K, Sherman L, Welch M. Studies of radioiodinated fibrinogen. I. Physicochemical properties of the ICl, chloramine-T, and electrolytic reaction products. Biochimica Et Biophysica Acta. 285: 404-13. PMID 4659649 DOI: 10.1016/0005-2795(72)90327-3 |
0.359 |
|
| 1971 |
Parks NJ, Krohn KA, Root JW. Chemistry of Nuclear Recoil 18F Atoms. IV. Hot F‐to‐HF and F‐to‐F2 Abstraction in CH3CF3 The Journal of Chemical Physics. 55: 2690-2698. DOI: 10.1063/1.1676481 |
0.629 |
|
| 1971 |
Krohn KA, Parks NJ, Root JW. Chemistry of nuclear recoil18f atoms. vi. approximate energetics and molecular dynamics in ch3cf3 The Journal of Chemical Physics. 55: 5785-5794. DOI: 10.1063/1.1675749 |
0.625 |
|
| 1971 |
Krohn KA, Parks NJ, Root JW. Chemistry of nuclear recoil18f atoms. v. mechanism and systematics in ch3cf3 The Journal of Chemical Physics. 55: 5771-5784. DOI: 10.1063/1.1675748 |
0.635 |
|
| Show low-probability matches. |
